Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Jianlisu sugammadex vs original sugammadex for reversal of postoperative residual neuromuscular blockade in pediatric patients
ChiCTR2500097055Phase 4Recruiting
- Sponsor
- Shanghai Children's Medical Center
- Start
- Feb 2025
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised trial of Sugammadex in Postoperative residual curarization (PORC) (2 arms), sponsored by Shanghai Children's Medical Center. Primary endpoint: Time for TOF ratio recovery from 0.2 to 0.9. Started Feb 2025; status: recruiting.
02
Drugs
Sugammadex
03
Conditions
Postoperative residual curarization (PORC)
Beyond the preview
Go deeper on ChiCTR2500097055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500097055.